Merus (NASDAQ:MRUS) Announces Quarterly Earnings Results

Merus (NASDAQ:MRUS) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.48, Zacks reports. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%.

Merus Price Performance

Shares of MRUS opened at $46.22 on Friday. Merus has a 1 year low of $37.77 and a 1 year high of $61.61. The firm has a market cap of $3.16 billion, a P/E ratio of -11.70 and a beta of 1.11. The stock has a 50 day simple moving average of $41.85 and a two-hundred day simple moving average of $46.84.

Analysts Set New Price Targets

MRUS has been the topic of several research analyst reports. Needham & Company LLC dropped their price objective on shares of Merus from $85.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday. HC Wainwright restated a “buy” rating and set a $85.00 price objective on shares of Merus in a research note on Monday, December 2nd. The Goldman Sachs Group began coverage on shares of Merus in a report on Thursday, November 21st. They set a “buy” rating and a $73.00 price target for the company. Citigroup raised their price objective on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Merus in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Merus has a consensus rating of “Buy” and an average price target of $85.77.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.